novo nordisk cuts prices for its glp-1 drugs. Wegovy price by up to 37% in India Novo's patent expires in India:

TLDR: GLP-1s are a massive, fast-growing drug class for type 2 diabetes and weight loss

Additionally, because many people with diabetes or who are overweight may control their condition with diet, other medications and therapies, or choose to not seek treatment, not all people who meet these clinical criteria would use GLP-1 drugs

Paul Murray, Swiss Re's CEO of Life & Health Reinsurance, commented on these findings in a press release, noting that GLP-1 drugs hold "significant promise to help us beat the obesity epidemic." CLICK HERE TO GET THE FOX NEWS APP "Our research underscores that the full benefit will come from going beyond medication," he wrote

Think of these meds as scaffolding: they support your weight loss but dont build the whole structure

95 In contrast, another study found that resistin levels were higher in T2D patients and individuals with impaired fasting glucose

This aligns with additional CivicScience data showing that GLP-1 users over-index as frozen food eaters